Advertisement

Biogen Idec Inc. and its Philadelphia-based partner Cardiokine Inc. have ended a collaboration on lixivaptan, a drug candidate for hyponatremia, or low sodium levels in the blood.

As a result, Cardiokine will regain all rights to the drug candidate, which is in Phase 3 clinical development.

SOURCE

Advertisement
Advertisement